A study set to be published in the journal Archives of Oral Biology in January 2025 explores the potential biological effects of cannabidiol (CBD) on oral squamous cell carcinoma cells.
Conducted by researchers from the University of Perugia in Italy, the study examines CBD as a possible adjuvant therapy in cancer treatment. The study was published online ahead of print by ScienceDirect.
Using in vitro models, the research tested the effects of CBD on human oral squamous cell carcinoma cells (HSC-3). The study utilized various concentrations of CBD, ranging from 1 µM to 100 µM, to assess cytotoxicity, cell viability, morphology, apoptosis, cell cycle arrest, and DNA damage. The researchers selected two key concentrations for analysis: 25 µM, identified as a toxic dose, and 6.25 µM, as a non-toxic dose.
Continue reading